As an example, inhibition of Egl nine homolog 1 (EGLN1) through the pan-EGLN1 inhibitor FG-4592 was found to selectively reduce the viability of HIF1A-high [278] or ARID1A-mutant [279] human ovarian cancer cell lines. Here, EGLN1 is linked to ovarian cancer.